Get the Stockscreener App
76.95
0.04%
0.03
After Hours:
77.34
0.39
+0.51%
Forte Biosciences Inc stock is traded at $76.95, with a volume of 1.26M.
It is up +0.04% in the last 24 hours and up +40.47% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$76.92
Open:
$76.94
24h Volume:
1.26M
Relative Volume:
1.01
Market Cap:
$1.63B
Revenue:
-
Net Income/Loss:
$-75.86M
P/E Ratio:
-15.07
EPS:
-5.1069
Net Cash Flow:
$-59.39M
1W Performance:
+0.08%
1M Performance:
+40.47%
6M Performance:
+170.00%
1Y Performance:
+573.23%
1-Day Range:
$76.92
$76.95
1-Week Range:
$76.82
$76.95
52-Week Range:
$10.11
$77.20
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
76.95 | 1.63B | 0 | -75.86M | -59.39M | -5.1069 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
What Forte Biosciences (FBRX) bankers see in $77 cash bid - Stock Titan
Forte Biosciences - The Pharma Letter
Forte Biosciences (NASDAQ:FBRX) Sets New 1-Year HighWhat's Next? - MarketBeat
Pharmaceutical Stocks Worth WatchingAugust 19th - MarketBeat
Forte (FBRX) Financial Update: Reported EPS Misses Expectations on the Day; Market Response: The Stock Ends Up 0.07% at the CloseEarnings Call Highlights - vinanet.vn
Forte Biosciences (NASDAQ:FBRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Biotech Stocks To Keep An Eye OnAugust 19th - MarketBeat
Forte (FBRX) Earnings Reading: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Share Move: The Session Ends Near the Prior Level in the Available RecordConsensus Miss Rate - vinanet.vn
Forte Biosciences (FBRX) cash tender clears antitrust - Stock Titan
Forte Biosciences (NASDAQ: FBRX) nears deal after U.S. antitrust wait expires - Stock Titan
argenx SE To Acquire Forte Biosciences Transcript - GuruFocus
Forte Biosciences (NASDAQ:FBRX): What Will the Market Learn About Development Strategy? - Kalkine Media
Avoiding Lag: Real-Time Signals in (FBRX) Movement - Stock Traders Daily
How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results - simplywall.st
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Forte Biosciences (FBRX): OrbiMed entities disclose 7.7% aggregate ownership stake - Stock Titan
Forte Biosciences (FBRX) Holds Near $76.86 as Key Resistance at $80.70 Caps Near-Term MoveIchimoku TK Cross - Vinanet
Forte Biosciences earnings on deck as $2.2 billion argenx deal nears - Investing.com Canada
Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77 - Moomoo
Forte Biosciences (FBRX) gains 5.6% stake holder in Affinity Asset Advisors - Stock Titan
Janus Henderson Group (FBRX) reports 1.89M Forte Biosciences shares under management - Stock Titan
Argenx stock holds near recent highs as half year 2026 update and Forte deal shape outlook - AD HOC NEWS
FBRX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FORTE BIOSCIENCES ($FBRX) Releases Q2 2026 Earnings - Quiver Quantitative
Forte Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Successful Equity Raise - Kalkine Media
Forte Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Forte Biosciences (FBRX) to be acquired by argenx in $77-per-share cash deal - Stock Titan
Forte Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Adage Capital discloses 700,000-share position in Forte Biosciences (FBRX) in ownership filing - Stock Titan
Forte Biosciences (FBRX) investor Glazer Capital now holds 1.46% stake - Stock Titan
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences - Yahoo Finance
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc.FBRX - Business Wire
argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition - Yahoo Finance
Forte Biosciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
FBRX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Janus Henderson Group Ltd. (NASDAQ: FBRX) discloses 2.5% beneficial stake in Forte - Stock Titan
Argenx Announces Commencement Of Tender Offer To Acquire Forte Biosciences, Inc. >ARGX.BT - Moomoo
argenx launches tender offer for Forte Biosciences at $77 per share - Investing.com
Forte Biosciences (NASDAQ:FBRX) Sees Large Volume IncreaseHere's Why - MarketBeat
Argenx Unit Launches Tender Offer to Acquire Forte Biosciences - marketscreener.com
Argenx Unit Kicks Off Tender Offer to Buy Forte Biosciences - marketscreener.com
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. - GlobeNewswire
Argenx ประกาศเริ่มกระบวนการเสนอซื้อหลักทรัพย์โดยสมัครใจ (Tender Offer) เพื่อเข้าซื้อกิจการของ Forte Biosciences, Inc. - Moomoo
Forte Biosciences (FBRX) to Release Earnings on Thursday - MarketBeat
Weekly Recap: Argenx $2.2B buyout at $77 and FB102 84% response rate - TradingView
Janus Henderson Group PLC Reduces Stake in Forte Biosciences, Inc. $FBRX - marketbeat.com
Price to earnings forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView
Enterprise value to revenue forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView
argenx SE (ARGX) Forte Biosciences, Inc.M&A CallSlideshow (NASDAQ:ARGX) 2026-07-31 - Seeking Alpha
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):